Absci Corp (ABSI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.65 (+4.10%), Market cap $0.76B, 52-week low–high $2.30 ~ $5.95.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The
Financial statements, price targets, institutional (13F) holdings and related news for Absci Corp are updated in real time on BlackAll Trade.
Absci Corp trades at $9.65 (+4.10%). Real-time quotes and charts are available on BlackAll Trade.
Absci Corp has a market cap of about $0.76B.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 cl